Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ofatumumab
Drug: First line DMT

First Posted Date: 2021-03-09

Last Posted Date: 2024-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 185

Registration Number: NCT04788615

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Spain

Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia

Phase 1

Terminated

Conditions: Amblyopia

Interventions: Device: Patching of the sound eye
Device: Binocular video games

First Posted Date: 2021-03-05

Last Posted Date: 2023-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT04784390

Locations: 🇨🇦
Novartis Investigative Site, Waterloo, Ontario, Canada

Special Drug Use Surveillance for Entresto Tablets

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: Entresto

First Posted Date: 2021-03-04

Last Posted Date: 2023-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 688

Registration Number: NCT04781881

Locations: 🇯🇵
Novartis Investigative Site, Yamaguchi, Japan

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Phase 4

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Brolucizumab

First Posted Date: 2021-03-01

Last Posted Date: 2024-04-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT04774926

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

Phase 1

Completed

Conditions: Hyperlipidemia

Interventions: Drug: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
Drug: Placebo
Drug: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)

First Posted Date: 2021-02-26

Last Posted Date: 2023-01-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT04774003

Locations: 🇨🇳
Novartis Investigative Site, Beijing, China

Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056

Phase 1

Withdrawn

Conditions: Cocaine Use Disorder

Interventions: Drug: Placebo
Drug: AFQ056

First Posted Date: 2021-02-25

Last Posted Date: 2021-07-01

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04771143

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

Completed

Conditions: Neovascular Age-related Macular Degeneration (nAMD)

Interventions: Drug: Brolucizumab

First Posted Date: 2021-02-21

Last Posted Date: 2024-07-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 81

Registration Number: NCT04764656

Locations: 🇵🇹
Novartis Investigative Site, Tomar, Portugal

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Phase 3

Active, not recruiting

Conditions: Hypercholesterolemia

Interventions: Drug: inclisiran sodium
Drug: Placebo

First Posted Date: 2021-02-21

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 345

Registration Number: NCT04765657

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 3

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Iptacopan

First Posted Date: 2021-02-10

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 250

Registration Number: NCT04747613

Locations: 🇺🇸
Mass Gen Hosp Cancer Center, Boston, Massachusetts, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸
City Of Hope, Duarte, California, United States

and more 8 locations

Managed Access Programs for INC424, Ruxolitinib

Conditions: Primary Myelofibrosis (PMF)
Post Polycythemia Myelofibrosis (PPV MF)
Thrombocythemia Myelofibrosis (PET-MF)
Severe/Very Severe COVID-19 Illness
Polycythemia Vera (PV)
Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)
Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

First Posted Date: 2021-02-09

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04745637

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy